Sickle cell kids' measles protection under the microscope

NCT ID NCT07356050

Recruiting now Knowledge-focused Sponsor: Children's Hospital Medical Center, Cincinnati Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether children with sickle cell disease (SCD) develop enough antibodies after getting the measles vaccine. Researchers will enroll 130 children aged 6 months to 6 years who are due for their measles shots. Blood samples will be taken a few weeks after each dose to check if their immune system responds well.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: measles vaccine
What this could lead to: If successful, this could confirm that standard measles vaccination works well for children with sickle cell disease, helping guide their care.
What could go wrong: This is an observational study, not testing a new treatment. It only measures immune response, not long-term protection or prevention of measles.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MEASLES VACCINATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sickle cell disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MEASLES VACCINATION SICKLE CELL ANEMIA SICKLE CELL DISEASE

Contacts and locations

Locations

Bugando Medical Centre
RECRUITING

Mwanza, Tanzania
Cincinnati Children's Hospital Medical Center
RECRUITING

Cincinnati, Ohio, 45229, United States
Korle Bu Teaching Hospital
RECRUITING

Accra, Ghana, Ghana

More trials for these conditions

Other studies related to the condition(s) this trial covers.